EXTENSIVE STAGE SMALL CELL LUNG CANCER

This large Phase 3 trial is testing whether a new drug called pumitamig (BNT327), when added to standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemotherapy) for people newly diagnosed with extensive-stage small-cell lung cancer. The stu…

This study is testing whether adding a new drug called tarlatamab to standard chemotherapy and immunotherapy helps people with advanced small-cell lung cancer live longer. Researchers will compare two treatment combinations in 330 participants who haven't received prior treatment…

This is the first study in people testing a new drug called ALPS12 for extensive stage small cell lung cancer that has returned after prior treatment. The main goals are to find a safe dose and see how the body handles the drug, while also checking for early signs that it might s…

This early-stage study is testing whether tarlatamab, given as an injection under the skin, is safe and tolerable for people with extensive stage small cell lung cancer that has worsened after initial treatment. The study will enroll about 220 adults to monitor side effects and s…

This early-stage study is testing whether a combination of two drugs, valemetostat and atezolizumab, is safe and effective as a maintenance therapy for people with extensive-stage small cell lung cancer. The goal is to help keep the cancer from growing or returning after patients…

This study is testing a new combination of drugs for people with extensive-stage small cell lung cancer who are starting their first treatment. The main goals are to find a safe dose and see if the combination can help control the cancer. The trial will enroll about 123 adults an…

This study is testing whether a drug called trilaciclib, given before chemotherapy, helps patients with advanced small cell lung cancer live longer. It also aims to see if it reduces severe side effects like low blood cell counts, which are common with chemotherapy. About 302 pat…

This study is testing if adding a drug called bevacizumab to a standard three-drug treatment can better control an aggressive type of lung cancer that has spread to the liver. It will involve 39 adults with extensive-stage small cell lung cancer who have not had prior treatment. …

This study is testing whether a new two-drug combination works better than current standard treatment for extensive-stage small cell lung cancer. Researchers will compare how long patients live and how well they tolerate the treatments. The trial involves 530 participants who hav…

This early-stage study is testing the safety and best dose of a two-drug combination (tarlatamab and AB248) for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goal is to see how well the body handles the drugs tog…

This study is testing if adding a short, intense course of targeted radiation to standard immunotherapy and chemotherapy helps people with extensive-stage small cell lung cancer live longer without their cancer getting worse. It is for adults newly diagnosed with this aggressive …

This study is testing whether a new two-part treatment can better control an aggressive form of lung cancer and keep it from getting worse. Previously untreated patients will first receive standard chemotherapy plus an immunotherapy drug, then continue with a maintenance therapy …

This study aims to see if a new blood analysis technology can predict how well patients with advanced small cell lung cancer will respond to a standard first-line treatment. The treatment combines an immunotherapy drug (tislelizumab) with chemotherapy. Researchers will analyze bl…